PMID- 27358556
OWN - NLM
STAT- MEDLINE
DCOM- 20170508
LR  - 20221207
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Efficacy and safety of gemcitabine plus erlotinib for locally advanced or 
      metastatic pancreatic cancer: a systematic review and meta-analysis.
PG  - 1961-72
LID - 10.2147/DDDT.S105442 [doi]
AB  - BACKGROUND: Pancreatic cancer is considered as a chemoresistant neoplasm with 
      extremely dismal prognosis. Gemcitabine is recommended as the standard agent for 
      locally advanced or metastatic pancreatic cancer. A series of trials have been 
      conducted to improve the outcome of advanced pancreatic cancer with other 
      anticancer drugs in combination with gemcitabine. Unfortunately, the designers of 
      the clinical trials failed to improve the poor prognosis of patients with 
      advanced pancreatic cancer. Erlotinib was the first additional drug that improved 
      the overall survival of patients with advanced pancreatic cancer with 
      gemcitabine. We performed this systematic review and meta-analysis to explore the 
      efficacy and safety of the combination of gemcitabine with erlotinib (GemErlo) 
      for patients with advanced pancreatic cancer using the currently available 
      evidence. METHODS: PubMed/MEDLINE, EMBASE, the Cochrane Library, and relevant 
      abstracts of major conferences were comprehensively searched. Data results on 
      objective response rate, disease control rate, and 1-year survival were pooled by 
      using MetaAnalyst with a random-effects model. Results on progression-free 
      survival and overall survival were only summarized descriptively. RESULTS: A 
      total of 24 studies with 1,742 patients with locally advanced or metastatic 
      pancreatic cancer treated with GemErlo were included. Combined objective response 
      rate was 14.4% (95% CI: 11.6%-17.7%), disease control rate was 55.0% (95% CI: 
      51.5%-58.5%), and 1-year survival rate was 28.5% (95% CI: 24.0%-33.4%). 
      Progression-free survival ranged from 2.63 to 9.6 months, and overall survival 
      varied from 6 to 10 months. As for the toxicity profile, the most common adverse 
      events (AEs) were hematologic reactions, skin rash, and gastrointestinal 
      reactions. Other severe AEs, which had low incidence, included treatment-induced 
      death and interstitial lung disease. CONCLUSION: Our study showed that GemErlo is 
      associated with reasonable activity in treating patients with locally advanced or 
      metastatic pancreatic cancer. Most of the AEs were tolerable, while some severe 
      AEs needed careful detection.
FAU - Wang, Yuan
AU  - Wang Y
AD  - School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, 
      University of Jinan, Jinan, Shandong, People's Republic of China.
FAU - Hu, Guo-Fang
AU  - Hu GF
AD  - School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, 
      University of Jinan, Jinan, Shandong, People's Republic of China.
FAU - Zhang, Qian-Qian
AU  - Zhang QQ
AD  - School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, 
      University of Jinan, Jinan, Shandong, People's Republic of China.
FAU - Tang, Ning
AU  - Tang N
AD  - School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, 
      University of Jinan, Jinan, Shandong, People's Republic of China.
FAU - Guo, Jun
AU  - Guo J
AD  - Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic 
      of China.
FAU - Liu, Li-Yan
AU  - Liu LY
AD  - Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic 
      of China.
FAU - Han, Xiao
AU  - Han X
AD  - Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic 
      of China.
FAU - Wang, Xia
AU  - Wang X
AD  - Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic 
      of China.
FAU - Wang, Zhe-Hai
AU  - Wang ZH
AD  - Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic 
      of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160613
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0W860991D6 (Deoxycytidine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Deoxycytidine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/*diagnosis
MH  - Erlotinib Hydrochloride/*administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Gemcitabine
PMC - PMC4912328
OTO - NOTNLM
OT  - advanced pancreatic cancer
OT  - chemotherapy
OT  - meta-analysis
OT  - targeted agent
EDAT- 2016/07/01 06:00
MHDA- 2017/05/10 06:00
PMCR- 2016/06/13
CRDT- 2016/07/01 06:00
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
PHST- 2016/06/13 00:00 [pmc-release]
AID - dddt-10-1961 [pii]
AID - 10.2147/DDDT.S105442 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Jun 13;10:1961-72. doi: 10.2147/DDDT.S105442. 
      eCollection 2016.